7.4 Spinal Cord Stimulation & Intrathecal Therapy

Spinal Cord Stimulation & Intrathecal Therapy

When non-interventional therapies, oral pharmacotherapy, and routine spine injections fail to manage refractory neuropathic pain or severe axial spasticity, advanced neuromodulation therapies become essential. Neuromodulation encompasses Spinal Cord Stimulation (SCS) and Intrathecal Drug Delivery Systems (ITDD).

Spinal Cord Stimulation (SCS)

Spinal Cord Stimulation involves the electrical stimulation of the dorsal columns of the spinal cord to modulate pain signaling prior to central brain processing.

Mechanism of Action: Gate Control Theory

SCS operates primarily through the Gate Control Theory of Pain (Melzack and Wall). Electrical current applied to the posterior epidural space depolarizes large-diameter, myelinated A- $\beta$ (A-beta) sensory fibers in the dorsal columns. Collateral branches of these A- $\beta$ fibers excite inhibitory interneurons (GABAergic and glycinergic) within the gelatinous substance (substantia gelatinosa) of the dorsal horn. Activated inhibitory interneurons release inhibitory neurotransmitters, effectively "closing the gate" and inhibiting the transmission of nociceptive signals carried by small, unmyelinated C fibers and thinly myelinated A- $\delta$ (A-delta) fibers to second-order spinothalamic tract neurons.

Stimulation Waveforms & Technologies

1. Traditional Tonic Stimulation (Paresthesia-Based): Low-frequency stimulation (50-100 Hz). Generates a pleasant tingling sensation (paresthesia) that must overlap the patient's anatomical painful region to achieve pain relief.
2. High-Frequency 10 kHz (HF10) Stimulation (Paresthesia-Free): Delivers 10,000 Hz electrical pulses. It provides robust pain relief without paresthesias by selectively modulating dorsal horn interneurons without driving A- $\beta$ fiber paresthesias. HF10 is highly effective for both axial low back pain and radicular leg pain.
3. Burst Stimulation: Delivers intermittent bursts of high-frequency pulses (e.g., 5 pulses at 500 Hz delivered 40 times per second). Mimics endogenous neuronal firing patterns and provides paresthesia-free pain relief while modulating medial affective pain pathways.

Clinical Indications

SCS is FDA-approved for chronic intractable pain of the trunk and limbs. Key PM&R indications include:

• Failed Back Surgery Syndrome (FBSS) / Post-Laminectomy Syndrome (persistent lumbar radiculopathy or axial back pain following spinal surgery).
• Complex Regional Pain Syndrome (CRPS Types I and II).
• Chronic Intractable Radiculopathy.
• Painful Diabetic Peripheral Neuropathy (DPN).
• Refractory Angina Pectoris and Ischemic Peripheral Vascular Disease.

Pre-Implantation Requirements & Trial Period

Before permanent SCS device implantation, patients must undergo a strict evaluation process:

1. Psychological Evaluation: Mandatory pre-trial clearance by a pain psychologist to rule out untreated active psychosis, severe unmanaged substance use disorder, active major depression with suicidal intent, or secondary gain issues that could compromise outcomes.
2. SCS Trial Period: Percutaneous epidural leads are placed under fluoroscopy (lead tips positioned at T8-T11 for lower extremity/axial back pain, or C2-C5 for upper extremity pain) and connected to an external trial pulse generator for 3 to 7 days.
3. Success Criteria: Permanent implantation is indicated ONLY if the trial achieves $\ge 50%$ pain reduction along with documented functional improvement and patient satisfaction.

Surgical Implantation & Complications

• Hardware Placement: Permanent leads (percutaneous cylindrical leads or surgical paddle leads placed via mini-laminectomy) are connected to an Implantable Pulse Generator (IPG) placed in a subcutaneous pocket in the upper gluteal or abdominal region.
• Complications: Lead migration (most common technical complication, causing loss of therapeutic coverage), epidural hematoma or abscess, dural puncture headache, seroma, and painful IPG pocket.

Intrathecal Drug Delivery Systems (ITDD)

Intrathecal Drug Delivery Systems ("pain pumps" or "baclofen pumps") deliver medications directly into the cerebrospinal fluid (CSF) within the subarachnoid space.

Principles & Advantages

Direct intrathecal administration bypasses the blood-brain barrier and systemic circulation. Consequently, therapeutic drug concentrations are achieved at spinal cord receptor sites using a fraction of the oral or intravenous dose (e.g., the intrathecal morphine dose is approximately 1/100th of the oral morphine dose). This dramatically minimizes systemic adverse effects (sedation, constipation, nausea).

System Components

An ITDD system consists of a subcutaneously implanted programmable pump (containing a drug reservoir and peristaltic motor) connected to a silicone intrathecal catheter. The catheter tip is advanced under fluoroscopy to the specific spinal level corresponding to pain or spasticity targets:

• Lower body pain / spasticity: T10-L1 level.
• Upper body pain: T1-T4 level.
• Diffuse severe spasticity: T1-T2 level.

FDA-Approved Intrathecal Medications

1. Morphine: Primary intrathecal opioid for chronic intractable non-malignant and cancer pain. Binds $\mu$-opioid receptors in the substantia gelatinosa of the dorsal horn.
   • Catheter Tip Granuloma: A critical complication of chronic intrathecal morphine infusion. Inflammatory non-infectious granulomatous masses can form at the distal catheter tip, leading to progressive spinal cord compression and myelopathy. New neurological deficits or loss of pain relief require urgent MRI or CT myelogram.
2. Ziconotide: Non-opioid peptide derived from the venom of the marine cone snail (Conus magnus).
   • Mechanism: Potent, selective blocker of N-type voltage-gated calcium channels on presynaptic primary nociceptive neurons in the dorsal horn, inhibiting glutamate and substance P release.
   • Clinical Nuance: Does NOT cause opioid tolerance or respiratory depression. Requires slow titration.
   • Contraindication: Contraindicated in patients with a history of psychosis, hallucinations, or severe psychiatric illness due to risk of treatment-emergent cognitive impairment, hallucinations, and acute psychosis.
3. Baclofen: GABA- $\beta$ (GABA-B) receptor agonist used to treat severe, recalcitrant spasticity of spinal (SCI, MS) or cerebral (CP, TBI, stroke) origin.
   • Intrathecal Baclofen (ITB) Trial: Requires a screening trial (bolus 50 mcg intrathecal injection) demonstrating significant reduction in Modified Ashworth Scale scores prior to pump implantation.

Intrathecal Baclofen Withdrawal (Emergency)

Abrupt cessation of intrathecal baclofen delivery (due to pump failure, catheter kink/dislodgement, low reservoir volume, or battery depletion) causes a life-threatening medical emergency.

• Clinical Presentation: Rapid onset of severe rebound spasticity, rigidity, hyperthermia ($>40^\circ\text{C}$), autonomic instability (tachycardia, labile BP), rhabdomyolysis, seizures, altered mental status, disseminated intravascular coagulation (DIC), and multi-organ failure. Symptoms mimic neuroleptic malignant syndrome or malignant hyperthermia.
• Emergency Management: Immediate administration of high-dose oral or IV baclofen, aggressive sedation with benzodiazepines (IV diazepam or midazolam), supportive intensive care, and urgent surgical/pump interrogation to restore intrathecal delivery.